News ASCO26: Celcuity punished as trial disappoints investors Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.
News FDA prior knowledge guide seeks to speed cell, gene therapy The FDA has laid out a framework to use 'prior knowledge' on manufacturing, non-clinical, and clinical data to support cell and gene therapy filings.
News ASCO26: In vivo CAR-Ts in the spotlight Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.
News ASCO26: After negative adcomm, AZ builds case for oral SERD AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA's review of the drug back on track.
News Abivax slides on phase 3 data in ulcerative colitis Shares in Abivax have tumbled after it announced phase 3 data with ulcerative colitis drug obefazimod that included several cases of cancer.
News ASCO26: Symptom-tracking app helps advanced cancer patients An app used to support people living with advanced cancer has helped them maintain quality of life, and also kept them out of hospital.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.